These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 8973689)

  • 21. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.
    Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
    J Urol; 2011 Jan; 185(1):67-71. PubMed ID: 21074202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.
    Giannakopoulos S; Gekas A; Alivizatos G; Sofras F; Becopoulos T; Dimopoulos C
    Br J Urol; 1998 Dec; 82(6):829-34. PubMed ID: 9883220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of bacillus Calmette-Guerin and interferon-alpha-2B on human bladder cancer in vitro.
    Zhang Y; Khoo HE; Esuvaranathan K
    Int J Cancer; 1997 May; 71(5):851-7. PubMed ID: 9180156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer.
    Gan YH; Mahendran R; James K; Lawrencia C; Esuvaranathan K
    Clin Immunol; 1999 Feb; 90(2):230-7. PubMed ID: 10080835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of bacillus Calmette-Guèrin and interferon alpha-2B on cytokine production in human bladder cancer cell lines.
    Zhang Y; Khoo HE; Esuvaranathan K
    J Urol; 1999 Mar; 161(3):977-83. PubMed ID: 10022737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do bacteriostatic urethral lubricants affect the clinical efficacy of intravesical bacillus Calmette-Guérin therapy?
    Loertzer H; Brake M; Horsch R; Keller H
    Urology; 2001 May; 57(5):900-5. PubMed ID: 11337290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ.
    Rosevear HM; Lightfoot AJ; Birusingh KK; Maymí JL; Nepple KG; O'Donnell MA;
    J Urol; 2011 Sep; 186(3):817-23. PubMed ID: 21788050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiproliferative effects of bacillus Calmette-Guerin and interferon alpha 2b on human bladder cancer cells in vitro.
    Pryor K; Stricker P; Russell P; Golovsky D; Penny R
    Cancer Immunol Immunother; 1995 Nov; 41(5):309-16. PubMed ID: 8536277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
    Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
    J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.
    Joudi FN; Smith BJ; O'Donnell MA;
    Urol Oncol; 2006; 24(4):344-8. PubMed ID: 16818189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP; Greenberg RE; Steinberg GD
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder.
    Glashan RW
    J Urol; 1990 Sep; 144(3):658-61. PubMed ID: 2201795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current state of immunotherapy for bladder cancer.
    Kassouf W; Kamat AM
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1037-46. PubMed ID: 15606331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.
    Jackson AM; Ivshina AV; Senko O; Kuznetsova A; Sundan A; O'Donnell MA; Clinton S; Alexandroff AB; Selby PJ; James K; Kuznetsov VA
    J Urol; 1998 Mar; 159(3):1054-63. PubMed ID: 9474231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.